Ketoprofen
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Ketoprofen: Acromesomelic dysplasia, Hunter-Thompson type
One-Sentence Summary
Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) originally used for arthritis conditions such as rheumatoid arthritis and osteoarthritis. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, but there are currently 0 clinical trials and 0 publications supporting this prediction. It rests on a model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ketoprofen is an NSAID that inhibits cyclooxygenase (COX) enzymes and reduces prostaglandin-mediated inflammation and pain. Its efficacy in arthritis conditions is established.
For the top-ranked prediction, the mechanistic link is not supported. Acromesomelic dysplasia, Hunter-Thompson type is a skeletal dysplasia caused by loss-of-function mutations in CDMP1/GDF5. COX inhibition is not expected to correct this genetic defect. The very high TxGNN score (0.9998) is a model output only, with no trial or literature backing.
Several lower-ranked predictions are more coherent with ketoprofen’s pharmacology, though none has supporting studies in the data compiled for this report:
- Juvenile arthritis due to defect in LACC1 (score 0.9974): NSAIDs are commonly used for symptom control in juvenile arthritis, but the link is indirect and symptomatic.
- Pseudoachondroplasia (score 0.9995): ketoprofen might relieve joint pain and inflammation, but it would not modify the underlying disease.
- Myosclerosis (score 0.9998): a weak, speculative link through symptomatic anti-inflammatory and analgesic effects.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 164666 | Ostofen 50mg Capsule | Strip of 10 capsules | Not stated |
| 115867 | Ketopatch 30mg Transdermal Patch | Packet of 1 transdermal patch | Not stated |
| 116005 | Ketofen 100mg Tablet | Strip of 10 tablets | Not stated |
| 236233 | Vofane 5mg Injection | Vial of 10 ml injection | Not stated |
| 121924 | Lupiflex 8 Tablet | Strip of 10 tablets | Not stated |
A total of 20 valid single-ingredient registrations exist. Formulations include oral capsules and tablets, transdermal patches and plasters, and an injection.
Safety Considerations
- Contraindications (from the TxGNN model (deep learning), not label text; these may reflect similarities the model learned between related diseases, not biological evidence): hypertension and hypertensive disorder, liver failure, kidney disease, peptic ulcer disease (including active), blood coagulation disease, myocardial infarction, coronary thrombosis, cardiovascular and heart disease, hemoglobinopathy, pyoureter.
- Drug Interactions: 226 interactions were identified in total. Examples from the compiled list:
- Moderate: acetylsalicylic acid, corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), metformin, glimepiride, chlorpropamide, mesalazine, balsalazide, naltrexone, potassium citrate and bicarbonate, picosulfuric acid, polyethylene glycol with electrolytes.
- Minor: famotidine, ranitidine, cimetidine, linaclotide.
Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on a model score, with no clinical trials or literature, and no plausible mechanistic link between COX inhibition and the genetic basis of acromesomelic dysplasia, Hunter-Thompson type. The knowledge-graph contraindications (cardiovascular, renal, hepatic, gastrointestinal) also warrant caution.
To proceed, the following is needed:
- Mechanism of action data for ketoprofen
- Package insert warnings and contraindications for the Indian market
- A dedicated literature and trial search for the more plausible candidates, especially spondyloarthropathy and LACC1-related juvenile arthritis, which are better suited as research questions than the top-ranked prediction
- Confirmation of the approved indications in the India licence records
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.